Cargando…
An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens
MYC translocations, a hallmark of Burkitt lymphoma, occur in 5-15% of diffuse large B-cell lymphoma, and have a negative prognostic impact. Numerical aberrations of MYC have also been detected in these patients, but their incidence and prognostic role are still controversial. We analyzed the clinica...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193495/ https://www.ncbi.nlm.nih.gov/pubmed/31399522 http://dx.doi.org/10.3324/haematol.2019.223891 |
_version_ | 1783528207751839744 |
---|---|
author | Schieppati, Francesca Balzarini, Piera Fisogni, Simona Re, Alessandro Pagani, Chiara Bianchetti, Nicola Micheli, Lorenzo Passi, Angela Ferrari, Samantha Maifredi, Adriana Bottelli, Chiara Leopaldo, Rossella Pellegrini, Vilma Facchetti, Fabio Rossi, Giuseppe Tucci, Alessandra |
author_facet | Schieppati, Francesca Balzarini, Piera Fisogni, Simona Re, Alessandro Pagani, Chiara Bianchetti, Nicola Micheli, Lorenzo Passi, Angela Ferrari, Samantha Maifredi, Adriana Bottelli, Chiara Leopaldo, Rossella Pellegrini, Vilma Facchetti, Fabio Rossi, Giuseppe Tucci, Alessandra |
author_sort | Schieppati, Francesca |
collection | PubMed |
description | MYC translocations, a hallmark of Burkitt lymphoma, occur in 5-15% of diffuse large B-cell lymphoma, and have a negative prognostic impact. Numerical aberrations of MYC have also been detected in these patients, but their incidence and prognostic role are still controversial. We analyzed the clinical impact of MYC increased copy number on 385 patients with diffuse large B-cell lymphoma screened at diagnosis for MYC, BCL2, and BCL6 rearrangements. We enumerated the number of MYC copies, defining as amplified those cases with an uncountable number of extra-copies. The prevalence of MYC translocation, increased copy number and amplification was 8.8%, 15%, and 1%, respectively. Patients with 3 or 4 gene copies, accounting for more than 60% of patients with MYC copy number changes, had a more favorable outcome compared to patients with >4 copies or translocation of MYC, and were not influenced by the type of treatment received as first-line. Stratification according to the number of MYC extra-copies showed a negative correlation between an increasing number of copies and survival. Patients with >7 copies or the amplification of MYC had the poorest prognosis. Patients with >4 copies of MYC showed a similar, trending towards worse prognosis compared to patients with MYC translocation. The survival of patients with >4 copies, translocation or amplification of MYC seemed to be superior if intensive treatments were used. Our study underlines the importance of fluorescence in situ hybridization testing at diagnosis of diffuse large B-cell lymphoma to detect the rather frequent and clinically significant numerical aberrations of MYC. |
format | Online Article Text |
id | pubmed-7193495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ferrata Storti Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-71934952020-05-11 An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens Schieppati, Francesca Balzarini, Piera Fisogni, Simona Re, Alessandro Pagani, Chiara Bianchetti, Nicola Micheli, Lorenzo Passi, Angela Ferrari, Samantha Maifredi, Adriana Bottelli, Chiara Leopaldo, Rossella Pellegrini, Vilma Facchetti, Fabio Rossi, Giuseppe Tucci, Alessandra Haematologica Articles MYC translocations, a hallmark of Burkitt lymphoma, occur in 5-15% of diffuse large B-cell lymphoma, and have a negative prognostic impact. Numerical aberrations of MYC have also been detected in these patients, but their incidence and prognostic role are still controversial. We analyzed the clinical impact of MYC increased copy number on 385 patients with diffuse large B-cell lymphoma screened at diagnosis for MYC, BCL2, and BCL6 rearrangements. We enumerated the number of MYC copies, defining as amplified those cases with an uncountable number of extra-copies. The prevalence of MYC translocation, increased copy number and amplification was 8.8%, 15%, and 1%, respectively. Patients with 3 or 4 gene copies, accounting for more than 60% of patients with MYC copy number changes, had a more favorable outcome compared to patients with >4 copies or translocation of MYC, and were not influenced by the type of treatment received as first-line. Stratification according to the number of MYC extra-copies showed a negative correlation between an increasing number of copies and survival. Patients with >7 copies or the amplification of MYC had the poorest prognosis. Patients with >4 copies of MYC showed a similar, trending towards worse prognosis compared to patients with MYC translocation. The survival of patients with >4 copies, translocation or amplification of MYC seemed to be superior if intensive treatments were used. Our study underlines the importance of fluorescence in situ hybridization testing at diagnosis of diffuse large B-cell lymphoma to detect the rather frequent and clinically significant numerical aberrations of MYC. Ferrata Storti Foundation 2020-05 /pmc/articles/PMC7193495/ /pubmed/31399522 http://dx.doi.org/10.3324/haematol.2019.223891 Text en Copyright© 2020 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher. |
spellingShingle | Articles Schieppati, Francesca Balzarini, Piera Fisogni, Simona Re, Alessandro Pagani, Chiara Bianchetti, Nicola Micheli, Lorenzo Passi, Angela Ferrari, Samantha Maifredi, Adriana Bottelli, Chiara Leopaldo, Rossella Pellegrini, Vilma Facchetti, Fabio Rossi, Giuseppe Tucci, Alessandra An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens |
title | An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens |
title_full | An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens |
title_fullStr | An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens |
title_full_unstemmed | An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens |
title_short | An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens |
title_sort | increase in myc copy number has a progressive negative prognostic impact in patients with diffuse large b-cell and high-grade lymphoma, who may benefit from intensified treatment regimens |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193495/ https://www.ncbi.nlm.nih.gov/pubmed/31399522 http://dx.doi.org/10.3324/haematol.2019.223891 |
work_keys_str_mv | AT schieppatifrancesca anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT balzarinipiera anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT fisognisimona anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT realessandro anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT paganichiara anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT bianchettinicola anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT michelilorenzo anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT passiangela anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT ferrarisamantha anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT maifrediadriana anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT bottellichiara anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT leopaldorossella anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT pellegrinivilma anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT facchettifabio anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT rossigiuseppe anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT tuccialessandra anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT schieppatifrancesca increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT balzarinipiera increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT fisognisimona increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT realessandro increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT paganichiara increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT bianchettinicola increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT michelilorenzo increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT passiangela increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT ferrarisamantha increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT maifrediadriana increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT bottellichiara increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT leopaldorossella increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT pellegrinivilma increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT facchettifabio increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT rossigiuseppe increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens AT tuccialessandra increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens |